TY - JOUR PY - 2018 DA - 2018// TI - The international classification of headache disorders, 3rd edition JO - Cephalalgia. VL - 38 UR - https://doi.org/10.1177/0333102417738202 DO - 10.1177/0333102417738202 ID - ref1 ER - TY - STD TI - GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 392(10159):1789–1858 ID - ref2 ER - TY - JOUR AU - Lipton, R. B. AU - Bigal, M. E. AU - Kolodner, K. AU - Stewart, W. F. AU - Liberman, J. N. AU - Steiner, T. J. PY - 2003 DA - 2003// TI - The family impact of migraine: population-based studies in the USA and UK JO - Cephalalgia. VL - 23 UR - https://doi.org/10.1046/j.1468-2982.2003.00543.x DO - 10.1046/j.1468-2982.2003.00543.x ID - Lipton2003 ER - TY - STD TI - American Headache Society (2018) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 59(1):1–18 ID - ref4 ER - TY - STD TI - Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP advisory group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 68(5):343–349 ID - ref5 ER - TY - JOUR AU - Loder, E. AU - Rizzoli, P. PY - 2018 DA - 2018// TI - Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018 JO - Headache. VL - 58 UR - https://doi.org/10.1111/head.13375 DO - 10.1111/head.13375 ID - Loder2018 ER - TY - JOUR AU - Ford, J. H. AU - Jackson, J. AU - Milligan, G. AU - Cotton, S. AU - Ahl, J. AU - Aurora, S. K. PY - 2017 DA - 2017// TI - A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns JO - Headache. VL - 57 UR - https://doi.org/10.1111/head.13202 DO - 10.1111/head.13202 ID - Ford2017 ER - TY - STD TI - Berger A, Bloudek LM, Varon SF, Oster G (2012) Adherence with migraine prophylaxis in clinical practice. Pain Pract. 12(7):541–549 ID - ref8 ER - TY - STD TI - Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 20(1):22–33 ID - ref9 ER - TY - JOUR AU - Peres, M. F. AU - Silberstein, S. AU - Moreira, F. AU - Corchs, F. AU - Vieira, D. S. AU - Abraham, N. PY - 2007 DA - 2007// TI - Patients' preference for migraine preventive therapy JO - Headache. VL - 47 UR - https://doi.org/10.1111/j.1526-4610.2007.00757.x DO - 10.1111/j.1526-4610.2007.00757.x ID - Peres2007 ER - TY - STD TI - Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 75(9):1080–1088 ID - ref11 ER - TY - JOUR AU - Skljarevski, V. AU - Matharu, M. AU - Millen, B. A. AU - Ossipov, M. H. AU - Kim, B. K. AU - Yang, J. Y. PY - 2018 DA - 2018// TI - Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial JO - Cephalalgia. VL - 38 UR - https://doi.org/10.1177/0333102418779543 DO - 10.1177/0333102418779543 ID - Skljarevski2018 ER - TY - JOUR AU - Detke, H. C. AU - Goadsby, P. J. AU - Wang, S. AU - Friedman, D. I. AU - Selzler, K. J. AU - Aurora, S. K. PY - 2018 DA - 2018// TI - Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study JO - Neurology. VL - 91 UR - https://doi.org/10.1212/WNL.0000000000006640 DO - 10.1212/WNL.0000000000006640 ID - Detke2018 ER - TY - JOUR AU - Detke, H. C. AU - Millen, B. A. AU - Zhang, Q. AU - Samaan, K. AU - Ailani, J. AU - Dodick, D. W. AU - Aurora, S. K. PY - 2020 DA - 2020// TI - Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies JO - Headache. VL - 60 UR - https://doi.org/10.1111/head.13691 DO - 10.1111/head.13691 ID - Detke2020 ER - TY - JOUR AU - Andreou, A. AU - Wright, P. AU - Detke, H. C. AU - Ruff, D. AU - Reuter, U. PY - 2019 DA - 2019// TI - Galcanezumab shows efficacy as early as day 1 after initial treatment vs. placebo for the prevention of episodic and chronic migraine JO - Cephalalgia. VL - 39 ID - Andreou2019 ER - TY - STD TI - Mulleners WM, Kim B, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 19:814–825 ID - ref16 ER - TY - JOUR AU - Tfelt-Hansen, P. AU - Pascual, J. AU - Ramadan, N. AU - Dahlof, C. AU - D'Amico, D. AU - Diener, H. C. PY - 2012 DA - 2012// TI - Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators JO - Cephalalgia. VL - 32 UR - https://doi.org/10.1177/0333102411430849 DO - 10.1177/0333102411430849 ID - Tfelt-Hansen2012 ER - TY - JOUR AU - Silberstein, S. AU - Tfelt-Hansen, P. AU - Dodick, D. W. AU - Limmroth, V. AU - Lipton, R. B. AU - Pascual, J. PY - 2008 DA - 2008// TI - Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults JO - Cephalalgia. VL - 28 UR - https://doi.org/10.1111/j.1468-2982.2008.01555.x DO - 10.1111/j.1468-2982.2008.01555.x ID - Silberstein2008 ER - TY - STD TI - Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2018) Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 38(5):815–832 ID - ref19 ER - TY - STD TI - Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2020) Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 40(10):1026–1044 ID - ref20 ER - TY - STD TI - Emgality (galcanezumab-gnlm) [package insert]. Eli Lilly and Company, Indianapolis, 2019. https://pi.lilly.com/us/emgality-uspi.pdf UR - https://www.pi.lilly.com/us/emgality-uspi.pdf ID - ref21 ER - TY - JOUR AU - Kielbasa, W. AU - Helton, D. L. PY - 2019 DA - 2019// TI - A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody JO - Cephalalgia. VL - 39 UR - https://doi.org/10.1177/0333102419840780 DO - 10.1177/0333102419840780 ID - Kielbasa2019 ER - TY - STD TI - Nichols R, Doty E, Sacco S, Ruff D, Pearlman E, Aurora SK (2019) Analysis of initial nonresponders to galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE-1, EVOLVE-2, and REGAIN randomized, double-blind, placebo-controlled studies. Headache. 59(2):192–204 ID - ref23 ER -